Neos Therapeutics, Inc. – Underwriting Agreement (June 29th, 2017)
Neos Therapeutics, Inc. – First Amendment to Facility Agreement (June 5th, 2017)
FIRST AMENDMENT TO FACILITY AGREEMENT (this Amendment), dated as of June 1, 2017, by and among NEOS THERAPEUTICS, INC., a Delaware corporation (Borrower), NEOS THERAPEUTICS COMMERCIAL, LLC, NEOS THERAPEUTICS BRANDS, LLC, NEOS THERAPEUTICS, LP, PHARMAFAB TEXAS, LLC (COLLECTIVELY, THE Guarantors) DEERFIELD PRIVATE DESIGN FUND III, L.P. (DPDF) and DEERFIELD SPECIAL SITUATIONS FUND, L.P. (DSSF, and together with DPDF collectively referred to as the Lenders and together with the Borrower and the Guarantors, the Parties).
Neos Therapeutics, Inc. – License Agreement by and Among Neos Therapeutics, Inc. And Shire Llc Dated as of March 6, 2017 (May 10th, 2017)
THIS LICENSE AGREEMENT (this Agreement) dated this the 6th day of March, 2017 (the Effective Date) is hereby entered into by and between Shire LLC, a Kentucky company with offices located at 9200 Brookfield Court, Florence, KY 41402 (Shire), and Neos Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with offices located at 2940 North Highway 360 #100, Grand Prairie, TX 75050 (Neos). Each of Shire and Neos is sometimes referred to herein, individually, as a Party and, collectively, as the Parties.
Neos Therapeutics, Inc. – Underwriting Agreement (February 3rd, 2017)
Ocera Therapeutics – Certificate of Amendment of Amended and Restated Certificate of Incorporation of Tranzyme, Inc. Pursuant to Section 242 of the General Corporation Law of the State of Delaware (July 16th, 2013)
The Board of Directors of the Corporation (the Board), pursuant to Section 242 of the Delaware General Corporations Law (DGCL), has duly adopted a resolution setting forth the following proposed amendment (the Amendment) to the Corporations certificate of incorporation as currently in effect (the Certificate of Incorporation) and declaring such amendment advisable, and the stockholders of the Corporation have duly approved and adopted the Amendment at a special meeting of stockholders called and held upon notice in accordance with Section 222 and Section 242 of the DGCL.
Ocera Therapeutics – Securities Purchase Agreement (April 29th, 2013)
This Securities Purchase Agreement (this Agreement) is dated as of April 23, 2013 by and among Tranzyme, Inc., a Delaware corporation (the Company), and each purchaser identified on the Schedule of Purchasers attached as Schedule 1 hereto (each, including its successors and assigns, a Purchaser and collectively, the Purchasers).
Ocera Therapeutics – Severance Agreement (February 12th, 2013)
This SEVERANCE AGREEMENT dated February 8, 2013 (the Agreement) is by and between TRANZYME, INC., a Delaware corporation (the Company), and DAVID MOORE, an individual residing in Cary, North Carolina (the Executive).